Long-Term Treatment With Finasteride Results in a Clinically Significant Reduction in Total Prostate Volume Compared to Placebo Over the Full Range of Baseline Prostate Sizes in Men Enrolled in the MTOPS Trial

No AccessJournal of UrologyAdult Urology1 Sep 2008Long-Term Treatment With Finasteride Results in a Clinically Significant Reduction in Total Prostate Volume Compared to Placebo Over the Full Range of Baseline Prostate Sizes in Men Enrolled in the MTOPS Trialis accompanied byHow Many Drugs for LUTS Due to BPH are Too Many? Steven A. Kaplan, Claus G. Roehrborn, John D. McConnell, Alan G. Meehan, Shailaja Surynawanshi, Jeannette Y. Lee, Jennifer Rotonda, John W. Kusek, Leroy M. Nyberg, and Medical Therapy of Prostatic Symptoms Research Group Steven A. KaplanSteven A. Kaplan Weill Cornell Medical College, New York, New York , Claus G. RoehrbornClaus G. Roehrborn The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas , John D. McConnellJohn D. McConnell The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas , Alan G. MeehanAlan G. Meehan Merck Research Laboratories, Rahway, New Jersey , Shailaja SurynawanshiShailaja Surynawanshi Merck Research Laboratories, Rahway, New Jersey , Jeannette Y. LeeJeannette Y. Lee University of Alabama at Birmingham, Birmingham, Alabama , Jennifer RotondaJennifer Rotonda Merck Research Laboratories, Rahway, New Jersey , John W. KusekJohn W. Kusek National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland , Leroy M. NybergLeroy M. Nyberg National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland , and Medical Therapy of Prostatic Symptoms Research Group View All Author Informationhttps://doi.org/10.1016/j.juro.2008.05.004AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: In the present analysis we examined data from the MTOPS (Medical Therapy of Prostatic Symptoms) trial to determine the effect of long-term finasteride treatment, either alone or in combination with doxazosin, on total prostate volume across the full range of baseline total prostate volume values in men enrolled in this study. Materials and Methods: In this trial a total of 3,047 patients with lower urinary tract symptoms were randomized to placebo, doxazosin (4 to 8 mg), finasteride (5 mg) or the combination of doxazosin and finasteride (average length of treatment 4.5 years). Total prostate volume was measured by transrectal ultrasound in all patients at baseline, yearly and at study end or at termination of participation. Results: Long-term treatment with finasteride led to a consistent reduction of approximately 25% in total prostate volume compared to placebo in men with a relatively small prostate (less than 25 to 30 ml), as well as in those with a moderate size (30 to less than 40 ml) or enlarged prostate (40 ml or greater) at baseline. Conclusions: In this MTOPS data analysis long-term (more than 4 years) treatment with finasteride, either alone or in combination with doxazosin, led to a consistent, clinically significant reduction in total prostate volume compared to placebo in patients with lower urinary tract symptoms and benign prostatic hyperplasia whose baseline prostate size ranged from relatively small (less than 25 to 30 ml) to enlarged (40 ml or greater). References 1 : The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med2003; 349: 2387. Google Scholar 2 : AUA guideline on management of benign prostatic hyperplasia (2003): Chapter 1: Diagnosis and treatment recommendations. J Urol2003; 170: 530. Link, Google Scholar 3 : Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials2003; 24: 224. Google Scholar © 2008 by American Urological AssociationFiguresReferencesRelatedDetailsCited bySharkey C, Long X, Wang Z, Al-Faouri R, Gershman B, Tsai L and Olumi A (2021) Zonal Growth Pattern of the Prostate Is Affected by Age and Body Mass IndexJournal of Urology, VOL. 207, NO. 4, (876-884), Online publication date: 1-Apr-2022.Bechis S, Otsetov A, Ge R and Olumi A (2018) Personalized Medicine for the Management of Benign Prostatic HyperplasiaJournal of Urology, VOL. 192, NO. 1, (16-23), Online publication date: 1-Jul-2014.Kaplan S, Lee J, Meehan A and Kusek J (2018) Long-Term Treatment With Finasteride Improves Clinical Progression of Benign Prostatic Hyperplasia in Men With an Enlarged Versus a Smaller Prostate: Data From the MTOPS TrialJournal of Urology, VOL. 185, NO. 4, (1369-1373), Online publication date: 1-Apr-2011.Related articlesJournal of Urology17 Jul 2008How Many Drugs for LUTS Due to BPH are Too Many? Volume 180Issue 3September 2008Page: 1030-1033 Advertisement Copyright & Permissions© 2008 by American Urological AssociationKeywordsprostatic hyperplasiaurinary tractdoxazosinfinasteridecombined modality therapyAcknowledgmentsMany investigators, study coordinators and patients contributed to the MTOPS trial. MTOPS was supported by cooperative agreements from the National Institute of Diabetes, Digestive and Kidney Diseases (U01 DK49977, U01 DK46416, U01 DK41418, U01 DK46429, U01 DK46431, U01 DK46437, U01 DK46437, U01 DK46468, U01 DK46472, U01 DK49880, U01 DK 49912, U01 DK49921, U01 DK49951, U01 DK49954, U01 DK49960, U01 DK49961, U01 DK49963, U01 DK49964, U01 DK49971, U01 DK49980), as well as by the National Center for Minority Health and Health Disparities, National Institutes of Health. Financial support and drug products for MTOPS were also provided by Merck and Pfizer.MetricsAuthor Information Steven A. Kaplan Weill Cornell Medical College, New York, New York Financial interest and/or other relationship with the National Institutes of Health. More articles by this author Claus G. Roehrborn The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas Financial interest and/or other relationship with Pfizer, GSK, Sanofi, AMS, Spectrum and Aeterna Zentaris. More articles by this author John D. McConnell The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas Financial interest and/or other relationship with GSK. More articles by this author Alan G. Meehan Merck Research Laboratories, Rahway, New Jersey Financial interest and/or other relationship with Merck. More articles by this author Shailaja Surynawanshi Merck Research Laboratories, Rahway, New Jersey Financial interest and/or other relationship with Merck. More articles by this author Jeannette Y. Lee University of Alabama at Birmingham, Birmingham, Alabama More articles by this author Jennifer Rotonda Merck Research Laboratories, Rahway, New Jersey Financial interest and/or other relationship with Merck. More articles by this author John W. Kusek National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland Financial interest and/or other relationship with Pfizer, Inc. More articles by this author Leroy M. Nyberg National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland More articles by this author Medical Therapy of Prostatic Symptoms Research Group More articles by this author Expand All Advertisement PDF downloadLoading ...